Magenta Therapeutics, which is developing novel therapies to make stem cell transplants more effective, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders intended to buy $40 million on the IPO (40% of the deal).
Magenta Therapeutics plans to list on the Nasdaq under the symbol MGTA. J.P. Morgan, Goldman Sachs and Cowen acted as lead managers on the deal.
